Navigation Links
Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome
Date:6/15/2009

Findings Published in Nature Medicine Suggest Broad Implications for the Treatment of Inflammatory and Autoimmune Disorders

SOUTH SAN FRANCISCO, Calif., June 15 /PRNewswire/ -- Proteolix, Inc. announced that in an article published today in Nature Medicine, Proteolix's selective immunoproteasome inhibitor PR-957 was shown to block disease progression in mouse models of rheumatoid arthritis in a dose-dependent manner and to completely eliminate visible signs of disease at the highest dose. The anti-inflammatory effect induced by PR-957 was rapid and long-lasting, lowering expression of multiple inflammatory mediators, including TNF-a and IL-6. Disease regression was evident 24 hours after dosing and a complete amelioration of disease was achieved with a single dose. When compared to anti-TNF-a therapy (etanercept), PR-957 mediated a more rapid resolution of clinical symptoms, including joint inflammation, and was more effective than etanercept in a model of aggressive arthritis.

These data were published in the June 14, 2009 online edition of Nature Medicine and will be published in the upcoming July 2009 print edition in an article titled: A Selective Inhibitor of the Immunoproteasome Subunit LMP7 Blocks Cytokine Production and Attenuates Progression of Experimental Arthritis. The authors of the article included members of the laboratory of Dr. Marcus Groettrup at the University of Constance (Konstanz, Germany) and researchers, led by Dr. Christopher Kirk, at Proteolix, Inc. (South San Francisco, CA), where the drug candidate was discovered and developed.

PR-957 is the first highly selective, small molecule inhibitor of the immunoproteasome. The proteasome is an intracellular complex present in most cells that mediates the degradation of intracellular proteins, including key components of pathways that contribute to cancer cell growth and immune signaling. It is a proven and val
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
2. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
3. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
4. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
5. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
8. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
9. Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis in Chickens
10. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
11. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)... , TAINAN, Taiwan, Nov. 19 /PRNewswire-Asi...ive pharmaceutical ingredients (APIs), announced t...mpound Safety Certification from,SafeBridge(R) Con...rm,s,competency and proficiency in the safe handli...Is), and applies to specific laboratories and,prod...
(Date:11/19/2009)... , ABBOTT PARK, Ill., Nov. 19 /PRNewswire-First...(NYSE: ABT ) as one of its Most Admired Corporat...e Deal honored Abbott as its Most Admired Dealmak...gic use of acquisitions and divestitures since Jan...reshaped its business portfolio with a focus on hi...
(Date:11/19/2009)... , Part of International Internet Week of Ac...e-USNewswire/ -- The U.S. Food and Drug Administra...rnational effort, called the International Interne...actions involving medical products. ,, (Logo: ...GO ) ,, During the effort, the FDA,s Office of ...
Breaking Medicine Technology:ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2Panel assesses evidence for the collection and use of family health history information 55523 1Panel assesses evidence for the collection and use of family health history information 55523 2Panel assesses evidence for the collection and use of family health history information 55523 3105th APSA Meeting worlds largest for the study of politics will be in Toronto Sept 3 6 55520 1105th APSA Meeting worlds largest for the study of politics will be in Toronto Sept 3 6 55520 2Beta blockers and stroke new insights into their use for older people 9715 1Beta blockers and stroke new insights into their use for older people 9715 2
(Date:11/22/2009)...teria are abundant, diverse and constant, but infl...ty of California, San Diego School of Medicine now... surface trigger a pathway that prevents excessive...ctually good for us," said Richard L. Gallo, MD, P... UCSD,s Division of Dermatology and the Dermatolog...
(Date:11/22/2009)...althSmart, an innovative healthcare benefit soluti...lly completed a recapitalization with Silver Point...rs. Silver Point Capital, L.P. is a private inves...recapitalization allows the Company to continue it..., (PRWEB) November 22, 200...
(Date:11/21/2009)... 21 Tonight, in a parti...tor Reid,s version of the government takeover of h...included in this bill; like the public option, emp...unding for elective abortion, which is the most on...bill provides subsidies for private plans that cov...
(Date:11/21/2009).... 21 A regional initiat...sis (river blindness) in the Americas has substant...ent years, as evidenced by a 31% decrease in the n...ation in six endemic countries. Results were repo...can Society of Tropical Medicine and Hygiene (ASTM...
(Date:11/21/2009)...novative medical apparel company launches men,s la... San Clemente, Calif. (PRWEB) November 2...dical apparel, today announced the launch of its m...9, a leading international trade fair for the medi... inaugurates its men,s collection with three varyi...
Breaking Medicine News(10 mins):Health News:Surface bacteria maintain skin's healthy balance 2Health News:HealthSmart Completes Recapitalization to Support Continued Growth, Daniel D. Crowley Named Chairman 2Health News:FRC: Senate Votes to Proceed with Abortion Funding Debacle 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4Health News:Medelita Introduces Men's Lab Coat Collection 2Health News:Medelita Introduces Men's Lab Coat Collection 3
... At a panel,discussion in Purcellville, VA on Marc...andidate for U.S. Congress in Virginia,s 10th Dist...sor Judy Feder, his opponent,in the June 10th Demo...eas for ending the war in Iraq, resolving the econ...
...he California,State Board of Pharmacy yesterday an...y authority to delay the implementation of E-Pedig...igree is the new track and trace,technology design...des with the recommendation that Dave Wilcox, RPh,...
...of Emergency Medicine is hosting the 11th annual S...um March 28-29 in Costa Mesa, Calif. As part of th...ll present research findings on a variety of relat...rgency department on-call coverage continues to wo...
...26 BD (Becton,Dickinson and Company) (NYSE: BDX ...ast of its second fiscal quarter 2008 earnings con... a.m. (ET). BD will issue a press release,detailin...stors and will be available for replay through,We...
...roundbreaking study conducted by University of Pit... the journal Brain (currently online) confirms tha...e beta-amyloid deposits found in the brains of pat... living patients. For a free-access link to the PD...
...t Data Research (TDR),President R.J. Slutz announc...nnual Step,N Forward fund raising campaign which w... "We are pleased to support Step,N Forward and the...ise the level of,care for our elders," said Target...
Other Medicine News:Health News:Democrat Mike Turner Backs Single-Payer Healthcare; Opponent Feder Undecided 2Health News:NCPA Statement on California's Delay of E-Pedigree Implementation 2Health News:UC Irvine researchers present latest findings at emergency medicine forum 2Health News:Study validates Pittsburgh Compound-B in identifying Alzheimer's disease brain toxins 2Health News:Study validates Pittsburgh Compound-B in identifying Alzheimer's disease brain toxins 3
Full-Height Radiation Barriers
Mobile Protective Shield
Center Mounted Barriers
ECONO GUARD
Medicine Products: